<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="section and outlined in this book, such as Ebola and" exact="Zika" post="viruses. For the clinician, the challenge is to distinguish"/>
 <result pre="(H7N9), chikungunya, yellow fever, cholera, hepatitis E, meningococcus, hepatitis A," exact="Zika" post="virus. 2016 Poliovirus, MERS-CoV, dengue fever, avian influenza (H7N9,"/>
 <result pre="monkeypox, chikungunya, enterohemorrhagic E. coli, yellow fever, Lassa fever, salmonellosis," exact="Zika" post="virus, Elizabethkingia, oropouche. 2015 Poliovirus, MERS-CoV, cholera, avian influenza"/>
 <result pre="Poliovirus, MERS-CoV, cholera, avian influenza (H7N9), chikungunya, plague, Lassa fever," exact="Zika" post="virus, measles, meningococcus, typhoid fever, Ebola. 2014 Ebola, avian"/>
 <result pre="meningococcus, typhoid fever, Ebola. 2014 Ebola, avian influenza (H7N9, H5N6)," exact="West Nile" post="virus, plague, Marburg, polio, MERS-CoV, chikungunya, enterovirus D68, cholera,"/>
 <result pre="influenza (H7N9), yellow fever, polio, cholera, meningococcus, novel coronavirus. 2012" exact="Yellow fever," post="novel coronavirus, Ebola, Marburg, Rift Valley fever, dengue fever,"/>
 <result pre="dengue fever, cholera, hantavirus pulmonary syndrome, enterovirus 71, meningococcus. 2011" exact="Yellow fever," post="polio, cholera, enterohemorrhagic E. coli, Ebola, measles, avian influenza"/>
 <result pre="a minority of patients can produce a severe hemorrhagic disease." exact="Chikungunya" post="and Ross River viruses can produce a generalized febrile"/>
 <result pre="severe joint pains that can persist for months. Japanese encephalitis," exact="West Nile," post="and the equine encephalitis viruses are classic viruses that"/>
 <result pre="that produce a meningo-encephalitis in 1% of the persons infected." exact="Yellow fever" post="and the filoviruses (Ebola and Marburg) are examples of"/>
 <result pre="Marburg) are examples of severe hemorrhagic fever viruses. The recent" exact="Zika" post="virus outbreak and birth defects associated with infection in"/>
 <result pre="hemorrhagic fever, and the filoviruses Marburg and Ebola. LibratyDaniel H.36.1" exact="Dengue" post="and Dengue Hemorrhagic Fever Abstract Dengue is the most"/>
 <result pre="and the filoviruses Marburg and Ebola. LibratyDaniel H.36.1 Dengue and" exact="Dengue" post="Hemorrhagic Fever Abstract Dengue is the most common and"/>
 <result pre="and Ebola. LibratyDaniel H.36.1 Dengue and Dengue Hemorrhagic Fever Abstract" exact="Dengue" post="is the most common and significant arboviral disease throughout"/>
 <result pre="dengue virus serotypes (DENVs 1–4). The clinical manifestations of a" exact="DENV" post="infection can range from an inapparent or mild febrile"/>
 <result pre="developing severe dengue is increased in individuals with sequential heterologous" exact="DENV" post="infections. Patients with dengue, or suspected dengue, who manifest"/>
 <result pre="dengue virus serotypes (DENVs 1–4). •The clinical manifestations of a" exact="DENV" post="infection can range from an inapparent or mild febrile"/>
 <result pre="risk for developing DHF/severe dengue is increased with sequential heterologous" exact="DENV" post="infections. •Patients with dengue, or suspected dengue, who manifest"/>
 <result pre="with early recognition and appropriate supportive care and management. Introduction" exact="Dengue" post="is the most prevalent and widespread human arboviral disease"/>
 <result pre="mosquitoes (Fig. 36.1.1 ). In the Asian tropics, all four" exact="DENV" post="serotypes co-circulate, creating a large region of hyper-endemicity. Dengue"/>
 <result pre="four DENV serotypes co-circulate, creating a large region of hyper-endemicity." exact="Dengue" post="outbreaks occur with predictable seasonality and periodicity. The majority"/>
 <result pre="biology, and environmental conditions, a shift in the dominant circulating" exact="DENV" post="serotype typically occurs every 4 to 6 years. The"/>
 <result pre="4 to 6 years. The shift in the dominant circulating" exact="DENV" post="serotype often leads to waves of large-scale epidemic dengue"/>
 <result pre="single infecting serotype. Over the past several decades, Asian genotype" exact="DENV" post="strains have spread throughout the Americas accompanied by increased"/>
 <result pre="spread throughout the Americas accompanied by increased co-circulation of multiple" exact="DENV" post="serotypes.5 As such, the dengue disease and transmission patterns"/>
 <result pre="Pathogenesis, and Pathology The human dengue cycle is maintained by" exact="DENV" post="transmission back and forth between mosquito vectors and viremic"/>
 <result pre="Thereafter, the virus rapidly disseminates, leading to viremia. The likely" exact="DENV" post="factories are tissue macrophages, dendritic cells, and adipocytes. The"/>
 <result pre="and is transient (hours to days). Primary infection with a" exact="DENV" post="serotype produces long-term protective immunity against re-infection with the"/>
 <result pre="(severe dengue) is increased 15- to 100-fold with sequential heterologous" exact="DENV" post="infections (secondary DENV infection) compared with primary DENV infections.3"/>
 <result pre="increased 15- to 100-fold with sequential heterologous DENV infections (secondary" exact="DENV" post="infection) compared with primary DENV infections.3 Most individuals with"/>
 <result pre="sequential heterologous DENV infections (secondary DENV infection) compared with primary" exact="DENV" post="infections.3 Most individuals with secondary DENV infections do not"/>
 <result pre="infection) compared with primary DENV infections.3 Most individuals with secondary" exact="DENV" post="infections do not develop severe dengue. Primary DENV infections"/>
 <result pre="with secondary DENV infections do not develop severe dengue. Primary" exact="DENV" post="infections in infants &amp;lt;12 months old also appear more"/>
 <result pre="more likely to lead to DHF/DSS (severe dengue) than primary" exact="DENV" post="infections in children or adults.12 Numerous risk factors have"/>
 <result pre="Features The most likely outcome of a primary or secondary" exact="DENV" post="infection is either asymptomatic infection or a mild undifferentiated"/>
 <result pre="non-specific constitutional symptoms. This is particularly true in children, whereas" exact="DENV" post="infections may be more likely to present as classic"/>
 <result pre="sparing. The appearance of this rash is pathognomonic for a" exact="DENV" post="infection. DHF/DSS is the dengue clinical syndrome whose distinguishing"/>
 <result pre="dengue, the majority of serious morbidity and mortality caused by" exact="DENV" post="infections is due to a vascular leakage syndrome with"/>
 <result pre="of vascular leakage, particularly in adults. Other uncommon complications of" exact="DENV" post="infections include hepatic necrosis, encephalopathy/encephalitis, and chorioretinitis. Unlike Zika"/>
 <result pre="of DENV infections include hepatic necrosis, encephalopathy/encephalitis, and chorioretinitis. Unlike" exact="Zika" post="virus infection, DENV infection during pregnancy has not been"/>
 <result pre="include hepatic necrosis, encephalopathy/encephalitis, and chorioretinitis. Unlike Zika virus infection," exact="DENV" post="infection during pregnancy has not been associated with congenital"/>
 <result pre="been associated with congenital malformations. TABLE 36.1.1 Case Definitions for" exact="Dengue" post="Hemorrhagic Fever/Dengue Shock Syndrome, Severe Dengue, and the Warning"/>
 <result pre="Shock Syndrome, Severe Dengue, and the Warning Signs for Severe" exact="Dengue" post="[alt-text] TABLE 36.1.1 Case Definition for Dengue Hemorrhagic Fever"/>
 <result pre="Signs for Severe Dengue [alt-text] TABLE 36.1.1 Case Definition for" exact="Dengue" post="Hemorrhagic Fever (DHF) and DHF Severity Classification Case Definition"/>
 <result pre="Fever (DHF) and DHF Severity Classification Case Definition for Severe" exact="Dengue" post="Warning Signs for Severe Dengue Signs/symptoms of dengue fever"/>
 <result pre="Classification Case Definition for Severe Dengue Warning Signs for Severe" exact="Dengue" post="Signs/symptoms of dengue fever and: 1.thrombocytopenia (platelet count &amp;lt;100,000/mm3),"/>
 <result pre="aminotransferase; AST, aspartate transaminase. Patient Evaluation, Diagnosis, and Differential Diagnosis" exact="Dengue" post="should be considered in all individuals in endemic regions,"/>
 <result pre="febrile illness of &amp;lt;10 to 14 days’ duration during the" exact="DENV" post="transmission season. The initial clinical findings in DENV infections"/>
 <result pre="during the DENV transmission season. The initial clinical findings in" exact="DENV" post="infections are fairly non-specific and can be difficult to"/>
 <result pre="malaria. In the appropriate clinical setting, measles, influenza, chikungunya, or" exact="Zika" post="virus infections are also possibilities. Early in the febrile"/>
 <result pre="possibilities. Early in the febrile course, the suspicion for a" exact="DENV" post="infection can be heightened by the presence of leukopenia,"/>
 <result pre="during the rainy season).17, 19 The critical phase of any" exact="DENV" post="infection is the 24 to 48 hours surrounding defervescence—generally"/>
 <result pre="5 to 7 of the febrile illness in a secondary" exact="DENV" post="infection. This is the time period when plasma leakage"/>
 <result pre="Laboratory diagnosis remains the most reliable way to identify a" exact="DENV" post="infection. Reverse transcriptase polymerase chain reaction (RT-PCR) can detect"/>
 <result pre="infections and 3 to 4 days in secondary infections. However," exact="DENV" post="RT-PCR is not routinely available in most clinical settings."/>
 <result pre="detected by antigen-detection assays that measure circulating levels of a" exact="DENV" post="non-structural protein, NS1. The timeline for detectable circulating soluble"/>
 <result pre="be affected by other flavivirus infections (e.g., Japanese encephalitis virus," exact="Zika" post="virus). Therefore the diagnostic sensitivity and specificity of anti-DENV"/>
 <result pre="with early recognition and appropriate supportive care and management. Prevention" exact="Dengue" post="prevention can be approached by strategies to minimize human–vector"/>
 <result pre="objects (e.g., used tires), and natural habitats (e.g., tree holes)." exact="Dengue" post="vaccine development has moved forward with encouraging advances. Given"/>
 <result pre="potential for increased disease severity upon sequential infection with heterologous" exact="DENV" post="serotypes, a general consensus has been that effective vaccination"/>
 <result pre="effective vaccination strategies will require simultaneous immunization to the four" exact="DENV" post="serotypes (tetravalent vaccines). A chimeric live-attenuated viral vaccine, where"/>
 <result pre="able to enhance the subsequent disease severity with a natural" exact="DENV" post="infection. Another tetravalent live-attenuated dengue vaccine (attenuated by a"/>
 <result pre="open up the possibility of severely halting, or even eradicating," exact="DENV" post="transmission in many endemic regions. References References 1VasilakisNWeaverSCThe history"/>
 <result pre="febrile illnesses in endemic populationsTrop Med Int Health1320081328134018803612 PowersAnn M.36.2" exact="Chikungunya" post="Fever Abstract Chikungunya fever is a re-emerging arboviral disease"/>
 <result pre="endemic populationsTrop Med Int Health1320081328134018803612 PowersAnn M.36.2 Chikungunya Fever Abstract" exact="Chikungunya" post="fever is a re-emerging arboviral disease characterized by the"/>
 <result pre="of the virus is by forest-dwelling Aedes species mosquitoes. Introduction" exact="Chikungunya" post="(CHIK) fever is an arboviral disease that is characterized"/>
 <result pre="cases of chikungunya fever. Fig. 36.2.2 Global distribution of autochthonous" exact="CHIKV" post="(as of 2016). Epidemiology The first recorded epidemic occurred"/>
 <result pre="first recorded epidemic occurred in Tanzania in 1952–1953. In Asia," exact="CHIKV" post="was first detected in Bangkok, Thailand, in 1958. In"/>
 <result pre="Reunion, Mayotte, Mauritius, and Seychelles, beginning in 2004.4, 5, 6" exact="CHIKV" post="then re-emerged in India in December 2005. The 2005–2006"/>
 <result pre="efficiently infect the secondary vector, A. albopictus.3 Imported cases of" exact="CHIKV" post="infection were reported from Europe and North and South"/>
 <result pre="of cases, but deaths are rarely encountered. Diagnosis Symptoms of" exact="CHIKV" post="infection can be clinically indistinguishable from dengue fever. Other"/>
 <result pre="diagnosis of CHIK include malaria, O'nyong nyong, Sindbis, Ross River," exact="West Nile," post="and Zika virus infections.9, 15, 16 The clinical laboratory"/>
 <result pre="include malaria, O'nyong nyong, Sindbis, Ross River, West Nile, and" exact="Zika" post="virus infections.9, 15, 16 The clinical laboratory findings in"/>
 <result pre="Because no vaccine or specific medication is yet available against" exact="CHIKV" post="infection, vector control is very important in controlling or"/>
 <result pre="and vector control of chikungunyaJ Infect Dis2142016S4596527920174 ChenLin H.WilsonMary E.36.3" exact="Zika" post="Abstract Zika virus is a Flavivirus identified in 1947"/>
 <result pre="control of chikungunyaJ Infect Dis2142016S4596527920174 ChenLin H.WilsonMary E.36.3 Zika Abstract" exact="Zika" post="virus is a Flavivirus identified in 1947 transmitted by"/>
 <result pre="in 1947 transmitted by Aedes mosquitoes. It remained obscure until" exact="Zika" post="outbreaks erupted in Yap in 2007, French Polynesia in"/>
 <result pre="Asia and Africa, and importations by travelers are well documented." exact="Zika" post="virus infection causes typically mild symptoms (or is asymptomatic),"/>
 <result pre="to severe microcephaly and other birth defects. The symptoms of" exact="Zika" post="resemble those of dengue and chikungunya virus infections, and"/>
 <result pre="Zika resemble those of dengue and chikungunya virus infections, and" exact="Zika" post="testing has limitations in terms of availability, sensitivity, and"/>
 <result pre="shedding in semen. Transfusion-related transmission has also occurred. Prevention of" exact="Zika" post="virus infection rests on avoidance of vector mosquitoes and"/>
 <result pre="during pregnancy to reduce the occurrence of congenital infection. Keywords" exact="Zika" post="congenital Zika syndrome microcephaly flavivirus arbovirus Guillain–Barré syndrome travel"/>
 <result pre="to reduce the occurrence of congenital infection. Keywords Zika congenital" exact="Zika" post="syndrome microcephaly flavivirus arbovirus Guillain–Barré syndrome travel in utero"/>
 <result pre="severe birth defects. •There is no anti-viral agent to treat" exact="Zika" post="virus infection; supportive care is indicated. •There is no"/>
 <result pre="for pregnant women and persons who are planning conception. Introduction" exact="Zika" post="virus, a single-stranded RNA virus of the Flaviviridae family,"/>
 <result pre="the Americas. Intense research activities have answered key questions about" exact="Zika" post="virus, its spread, and control, but gaps in knowledge"/>
 <result pre="its spread, and control, but gaps in knowledge remain. Epidemiology" exact="Zika" post="virus, first isolated from a sentinel rhesus monkey in"/>
 <result pre="virus, first isolated from a sentinel rhesus monkey in the" exact="Zika" post="forest in Uganda in 1947, was found in the"/>
 <result pre="in mild human infections in Africa and Asia. In 2007" exact="Zika" post="virus caused a large outbreak on Yap Island (western"/>
 <result pre="a major outbreak in French Polynesia in 2013 to 2014.2" exact="Zika" post="virus was first associated with recognized outbreaks in Brazil"/>
 <result pre="but recent analyses using sequencing, molecular mapping, and modeling suggest" exact="Zika" post="reached the Americas as early as 2013, with cryptic"/>
 <result pre="and ecoclimatic conditions are favorable.7 Fig. 36.3.1 Recent status of" exact="Zika" post="virus transmission. Transmission Infection is spread primarily via infected"/>
 <result pre="which can survive in more temperate areas, can also transmit" exact="Zika" post="virus. These mosquito vectors infest most sub-tropical and tropical"/>
 <result pre="chikungunya (and co-transmission can occur). In the past 10 years," exact="Zika" post="transmission has been reported from at least 84 countries.6"/>
 <result pre="Zika transmission has been reported from at least 84 countries.6" exact="Zika" post="virus can be transmitted vertically in A. aegypti mosquitoes."/>
 <result pre="aegypti provides a suitable environment for transmission. Of the 5413" exact="Zika" post="virus disease cases (excluding congenital cases) reported in the"/>
 <result pre="virus up to 69 days. In a longitudinal assessment of" exact="Zika" post="virus RNA in body fluids, 95% of men had"/>
 <result pre="is vector borne and how much infection is sexually transmitted." exact="Zika" post="virus particles and RNA have been found in breast"/>
 <result pre="island found 1.1% viremic.13 Pathogenesis and Pathology Perinatal transmission of" exact="Zika" post="virus was reported to occur in the French Polynesia"/>
 <result pre="Polynesia outbreak in 2013 to 2014, but the association between" exact="Zika" post="virus and microcephaly was not recognized until the observations"/>
 <result pre="was done in 2016 based on serologic and surveillance data.14" exact="Zika" post="virus can infect the placenta, reach the developing fetus,"/>
 <result pre="live-born infants from completed pregnancies with laboratory evidence of possible" exact="Zika" post="virus infection), about 5% had Zika-associated birth defects. The"/>
 <result pre="4%, respectively, for first, second, and third trimesters).18 Clinical Features" exact="Zika" post="virus seroprevalence studies in Yap and French Polynesia estimated"/>
 <result pre="Rarely, some severe complications in adults have been attributed to" exact="Zika" post="virus infection, particularly neurologic disorders (GBS, myelitis, demyelinating polyneuropathy,"/>
 <result pre="immune-mediated thrombocytopenia.23, 25, 26, 27 GBS occurred in about 1/4000" exact="Zika" post="infections in studies from French Polynesia and Brazil, at"/>
 <result pre="(6%), and 51% have chronic pain.27 As described earlier, congenital" exact="Zika" post="syndrome resulting from infection during pregnancy is associated with"/>
 <result pre="Patient Evaluation, Diagnosis, and Differential Diagnosis During acute infection with" exact="Zika" post="virus, laboratory findings may reveal leukopenia, lymphopenia, thrombocytopenia, and"/>
 <result pre="be mildly elevated, as well as transaminases. Recommendations for confirmatory" exact="Zika" post="virus testing vary among countries and have evolved over"/>
 <result pre="recommendations and interpretation of results for symptomatic persons with possible" exact="Zika" post="virus exposure. (A) Pregnant women. Testing recommendations and interpretation"/>
 <result pre="recommendations and interpretation of results for symptomatic persons with possible" exact="Zika" post="virus exposure. (B) Non-pregnant women. Definitive Zika diagnosis can"/>
 <result pre="persons with possible Zika virus exposure. (B) Non-pregnant women. Definitive" exact="Zika" post="diagnosis can be made by detection of viral RNA"/>
 <result pre="symptom onset or exposure28, 29 (see Fig. 36.3.2). Detection of" exact="Zika" post="IgM by IgM-capture enzyme-linked immunosorbent assay (MAC-ELISA) followed by"/>
 <result pre="plaque reduction neutralization test (PRNT) can also establish the diagnosis." exact="Zika" post="IgM may be reactive when performed 2 to 12"/>
 <result pre="to 12 weeks after exposure, but can persist longer. Unfortunately," exact="Zika" post="serology cross-reacts with other flaviviruses, and PRNT, which is"/>
 <result pre="where IgG is available to assess past infection and immunity," exact="Zika" post="IgG is not available in the United States. There"/>
 <result pre="and Drug Administration (FDA)–licensed diagnostic tests for the diagnosis of" exact="Zika" post="virus infection, but several diagnostic tests are available under"/>
 <result pre="performs PRNT. In October 2017, the FDA approved the first" exact="Zika" post="test for screening blood donations. The main differential diagnoses"/>
 <result pre="test for screening blood donations. The main differential diagnoses for" exact="Zika" post="virus infection are other viruses transmitted by Aedes mosquitoes,"/>
 <result pre="followed by PRNT is desirable. Other diagnoses that may resemble" exact="Zika" post="virus infections include rubeola, rubella, parvovirus, West Nile virus,"/>
 <result pre="that may resemble Zika virus infections include rubeola, rubella, parvovirus," exact="West Nile" post="virus, and many other viruses, as well as leptospirosis,"/>
 <result pre="and malaria. Treatment and Prevention Treatment for the typical uncomplicated" exact="Zika" post="virus infection aims to provide symptomatic relief. There is"/>
 <result pre="provide symptomatic relief. There is no known specific medication targeting" exact="Zika" post="virus. However, research is underway to assess the effect"/>
 <result pre="underway to assess the effect of some existing drugs on" exact="Zika" post="virus. Preliminary investigations have identified some candidate drugs: emricasan,"/>
 <result pre="lactoferrin.9 Further evaluation is needed regarding their potential activity against" exact="Zika" post="virus. Currently there is no vaccine to prevent Zika"/>
 <result pre="against Zika virus. Currently there is no vaccine to prevent" exact="Zika" post="virus infection but multiple candidate vaccines are under development"/>
 <result pre="and sexual transmission is fundamental in prevention. The impact of" exact="Zika" post="virus infection is most consequential during pregnancy; thus preventing"/>
 <result pre="conception include the following: avoid travel to areas with active" exact="Zika" post="virus transmission, take measures to avoid mosquito bites, and"/>
 <result pre="to reduce risk from sexual transmission. In areas with active" exact="Zika" post="virus transmission, vector control measures are essential. Updated epidemiology"/>
 <result pre="Med3602420092536254319516034 2MussoDGublerDJZika virusClin Microbiol Rev293201648752427029595 3FariaNRQuickJClaroIMEstablishment and cryptic transmission of" exact="Zika" post="virus in Brazil and the AmericasNature5467658201740641028538727 4WorobeyMEpidemiology: molecular mapping"/>
 <result pre="virus in Brazil and the AmericasNature5467658201740641028538727 4WorobeyMEpidemiology: molecular mapping of" exact="Zika" post="spreadNature546201735528538722 5ZhangQSunKChinazziMSpread of Zika virus in the AmericasPNAS114222017E43344328442561 6WHOSituation"/>
 <result pre="the AmericasNature5467658201740641028538727 4WorobeyMEpidemiology: molecular mapping of Zika spreadNature546201735528538722 5ZhangQSunKChinazziMSpread of" exact="Zika" post="virus in the AmericasPNAS114222017E43344328442561 6WHOSituation Report: Zika virus, microcephaly,"/>
 <result pre="spreadNature546201735528538722 5ZhangQSunKChinazziMSpread of Zika virus in the AmericasPNAS114222017E43344328442561 6WHOSituation Report:" exact="Zika" post="virus, microcephaly, Guillain-Barre syndromehttp://www.who.int/emergencies/zika-virus/situation-report/10-march-2017/en/2017 7collab: The Singapore Study GroupOutbreak"/>
 <result pre="virus, microcephaly, Guillain-Barre syndromehttp://www.who.int/emergencies/zika-virus/situation-report/10-march-2017/en/2017 7collab: The Singapore Study GroupOutbreak of" exact="Zika" post="virus infection in Singapore: an epidemiological, entomological, virological, and"/>
 <result pre="epidemiological, entomological, virological, and clinical analysisLancet Infect Dis17201781382128527892 8AlthouseBMVasilakisNSallAAPotential for" exact="Zika" post="virus to establish a sylvatic transmission cycle in the"/>
 <result pre="Dis10122016e000505527977671 9HamerDHWilsonMEJeanJChenLHEpidemiology, prevention, and potential future treatments of sexually transmitted" exact="Zika" post="virus infectionCurr Infect Dis Rep19420171628281082 10Paz-BaileyGRosenbergESDoyleKPersistence of Zika virus"/>
 <result pre="sexually transmitted Zika virus infectionCurr Infect Dis Rep19420171628281082 10Paz-BaileyGRosenbergESDoyleKPersistence of" exact="Zika" post="virus in body fluids – final reportN Engl J"/>
 <result pre="reportN Engl J Med3791320171234124328195756 11MottaIJFSpencerBRCordeiro da SilvaSGEvidence for transmission of" exact="Zika" post="virus by platelet transfusionN Engl J Med37520161101110327532622 12GalelSAWilliamsonPCBuschMPFirst Zika-positive"/>
 <result pre="in the continental United StatesTransfusion57201776276928164310 13KuehnertMJBasavarajuSVMoseleyRRScreening of blood donations for" exact="Zika" post="virus infection – Puerto Rico, April 3-June 11, 2016MMWR"/>
 <result pre="April 3-June 11, 2016MMWR Morb Mortal Wkly Rep65201662762827337368 14CauchemezSBesnardMBompardPAssociation between" exact="Zika" post="virus and microcephaly in French Polynesia, 2013-15: a retrospective"/>
 <result pre="and microcephaly in French Polynesia, 2013-15: a retrospective studyLancet3871003320162125213226993883 15HoneinMADawsonALPetersenEEUS" exact="Zika" post="pregnancy registry collaboration. Birth defects among fetuses and infants"/>
 <result pre="fetuses and infants of US women with evidence of possible" exact="Zika" post="virus infection during pregnancyJAMA31712017596827960197 16MooreCAStaplesJEDobynsWBCharacterizing the pattern of anomalies"/>
 <result pre="infection during pregnancyJAMA31712017596827960197 16MooreCAStaplesJEDobynsWBCharacterizing the pattern of anomalies in congenital" exact="Zika" post="syndrome for pediatric cliniciansJAMA Pediatr1713201728829527812690 17SousaAQCavalcanteDIMFrancoLMPostmortem findings for 7"/>
 <result pre="pediatric cliniciansJAMA Pediatr1713201728829527812690 17SousaAQCavalcanteDIMFrancoLMPostmortem findings for 7 neotates with congenital" exact="Zika" post="virus infectionEmerg Infect Dis2320171164116728459414 18Shapiro-MendozaCRiceMEGalangRRPregnancy outcomes after maternal Zika"/>
 <result pre="congenital Zika virus infectionEmerg Infect Dis2320171164116728459414 18Shapiro-MendozaCRiceMEGalangRRPregnancy outcomes after maternal" exact="Zika" post="virus infection during pregnancy- U.S. territories, January 1, 2016-April"/>
 <result pre="characterization, epidemiological and virological aspectsPLoS Negl Trop Dis1042016e000463627070912 21DirlikovERyffKRTorres-AponteJUpdate: ongoing" exact="Zika" post="virus transmission, Puerto Rico, November 1, 2015 – April"/>
 <result pre="2015 – April 14, 2016MMWR Morb Mortal Wkly Rep6517201645145527149205 22ArmstrongPHennesseyMAdamsMTravel-associated" exact="Zika" post="virus disease cases among U.S. Residents - United States,"/>
 <result pre="2015-February 2016MMWR Morb Mortal Wkly Rep6511201628628927023833 23HamerDHBarbreKAChenLHGeoSentinel surveillance network. travel-associated" exact="Zika" post="virus disease acquired in the Americas through February 2016:"/>
 <result pre="analysisAnn Intern Med166220179910827893080 24GoodmanABDziubanEJPowellKCharacteristics of children aged &amp;lt;18 years with" exact="Zika" post="virus disease acquired postnatally - U.S. States, January 2015-July"/>
 <result pre="2016MMWR Morb Mortal Wkly Rep653920161082108527711041 25Cao-LormeauVMBlakeAMonsSGuillain-Barré syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: a case-control studyLancet3871002720161531153926948433 26ParraBLizarazoJJiménez-ArangoJAGuillain-Barré"/>
 <result pre="in French Polynesia: a case-control studyLancet3871002720161531153926948433 26ParraBLizarazoJJiménez-ArangoJAGuillain-Barré syndrome associated with" exact="Zika" post="virus infection in ColombiaN Engl J Med3751620161513152327705091 27Da SilvaIRFFronteraJABispo"/>
 <result pre="J Med3751620161513152327705091 27Da SilvaIRFFronteraJABispo de FilippisAMNeurologic complications associated with the" exact="Zika" post="virus in Brazilian adultsJAMA Neurol741020171190119828806453 28OduyeboTPolenKDWalkeHTUpdate: interim guidance for"/>
 <result pre="for health care providers caring for pregnant women with possible" exact="Zika" post="virus exposure - United States (including U.S. territories), July"/>
 <result pre="Morb Mortal Wkly Rep6629201778179328749921 29CDCGuidance for US Laboratories Testing for" exact="Zika" post="Virus Infectionhttps://www.cdc.gov/zika/laboratories/lab-guidance.html2017 DeyeGregoryKorenMichael36.4 O'nyong Nyong Fever Abstract O'nyong nyong"/>
 <result pre="of serologic results because of a well-known, one-way cross-reactivity with" exact="CHIKV" post="(i.e., patients previously infected with chikungunya will develop cross-reactive"/>
 <result pre="molecular biology approaches are more indicated to confirm MAYV and/or" exact="CHIKV" post="infection; indeed, the real-time polymerase chain reaction (PCR) is"/>
 <result pre="of fever, arthralgia, and rash, particularly dengue, Oropouche, chikungunya, and" exact="Zika" post="fever viruses. The laboratory diagnosis of Mayaro fever either"/>
 <result pre="ELISA, and neutralization assays.31 Differential diagnosis may include ehrlichiosis, anaplasmosis," exact="West Nile" post="virus infection, rickettsial infection, leptospirosis, and other etiologies. Treatment"/>
 <result pre="outbreaks have notably been reported in conjunction with outbreaks of" exact="West Nile" post="virus infection as they share the same Culex mosquito"/>
 <result pre="(Pogosta) virus in different parts of FinlandRheumatology425200363263612709538 8McIntoshBJuppPDos SantosIMeenehanGEpidemics of" exact="West Nile" post="and Sindbis viruses in South Africa with Culex (Culex)"/>
</results>
